Clinical trials: Digestive Infection
Hepatitis C
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Patients who are Hepatitis C Negative (HCV negative) and are on the waiting list for a lung transplant at NYULH who consent to participate in this study will receive a lung transplant from a deceased donor that is HCV positive.
- Trial name
- NCT03523871
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hepatitis C, Chronic
Drug-drug Interaction of BI 201335 and Microgynon
This study will investigate possible effect of multiple oral doses of BI 201335 on the steady state pharmacokinetics of ethinylestradiol and levonogestrel
- Trial name
- NCT01570244
- Testing
- levonorgestrel, Ethinylestradiol, BI 201335
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)
The objective of this study is to compare the efficacy of peginterferon alfa-2b (PegIFN-2b) monotherapy administered at a dose of 0.5 ug/kg vs stronger neo minophagen C (SNMC) in participants with chronic hepatitis C (CHC) and…
- Trial name
- NCT00686881
- Testing
- Peginterferon alfa-2b (PegIFN-2b), Comparator: Stronger neo minophagen C (SNMC)
- Volunteers
- 261 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.
- Trial name
- HBRN (NCT01369199)
- Testing
- Entecavir and peginterferon
- Where
- 21 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
This 3 arm study will assess the efficacy and safety of PEGASYS alone, or in combination with Adefovir or Entecavir in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT00922207
- Testing
- Adefovir, Entecavir, peginterferon alfa-2a [Pegasys]
- Where
- 9 sites in Taiwan
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide…
- Trial name
- B-Clear (NCT04449029)
- Testing
- GSK3228836, Nucleos(t)ide therapy
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 457 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Prevalence of HBV in Pregnant Women Attending Antenatal Care in Tanzania
Chronic Hepatitis B virus (HBV) infection is a neglected disease with devastating consequences, particularly in countries with limited resources for the health sector.
- Trial name
- HBVPMTCT (NCT04325542)
- Testing
- HBSAg (sure screen test)
- Where
- Tanzania
- Volunteers
- 743 people
- Sponsor
- Medical Mission Institute, Germany
Hepatitis C, Chronic
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic…
- Trial name
- NCT02461745
- Testing
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Infections, Rotavirus
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
This post marketing surveillance will evaluate reactogenicity and safety data of human rotavirus vaccine when administered to healthy infants according to the Prescribing Information in India.
- Trial name
- NCT00938327
- Testing
- Rotarix™
- Where
- 12 sites in India
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Liver Diseases
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Clearance of HCV infection requires early and multi-specific HLA class I restricted CD8+ T cell and class II restricted CD4+ T cell responses to both structural (Core) and non-structural HCV proteins (NS3, NS4A, NS5A, NS5B).
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Hepatitis, Virus Diseases
- Trial name
- NCT03119025
- Testing
- Autologous DC-vaccines
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Russian Academy of Medical Sciences
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
HepaGam B Hepatitis B Immune Globulin (HBIG) solution contains 10% maltose, which could possibly interfere with the measurement of glucose levels when using glucose non-specific tests.
- Trial name
- NCT00998426
- Testing
- glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Georgetown University
Hepatitis C, Chronic
Dose Ranging of GSK2336805 in Combination Therapy
GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- HAI115879 (NCT01648140)
- Testing
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 286 people
- Sponsor
- GlaxoSmithKline
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Major Depressive Disorder, Hepatitis C, Chronic
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
- Trial name
- NCT00166296
- Testing
- Escitalopram
- Where
- 15 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Germans Trias i Pujol Hospital
Hepatitis C
Armodafinil for Patients Starting Hepatitis C Virus Treatment
Fatigue is one of the most common side effects of the treatment of hepatitis C infection with pegylated interferon and ribavirin, and is a major cause of treatment discontinuation.
- Trial name
- NCT01470651
- Testing
- Armodafinil, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatment because of concerns about adherence, effectiveness, and reinfection.
- Trial name
- NCT00725751
- Testing
- Pegylated interferon alfa-2b (PegIFN-2b), Ribavirin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus-Infection
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.
- Trial name
- NCT01153269
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 8 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Abbott
Hepatitis C
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer…
- Trial name
- NCT00056862
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Hepatitis A
Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared
To evaluate the persistence of anti-hepatitis A virus (HAV) and anti-hepatitis B surface antigen (HBs) antibodies up to 2, 3, 4 and 5 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00197184
- Testing
- Twinrix™ Adult, Twinrix™ Junior
- Where
- 7 sites in Australia, Belgium and 1 more
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.